Rx Product News

Published Online: Friday, December 13, 2013
Follow Pharmacy_Times:

Zorvolex

Marketed by: Iroko Pharmaceuticals, LLC
Indication: The FDA has approved Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug, for the treatment of mild to moderate acute pain in adults. The recommended dosage is 18 or 35 mg orally 3 times a day. The lowest effective dosage for the shortest duration consistent with individual patient treatment goals should be used. Zorvolex capsules are not interchangeable with other formulations of oral diclofenac even if the milligram strength is the same.
Dosage Form: Capsules: 18 or 35 mg
For More Information: https://www.zorvolex.com


Khedezla
Marketed by: Osmotica Pharmaceutical Corp
Indication: The FDA has approved Khedezla (desvenlafaxine) extended-release tablets, a serotonin and norepinephrine reuptake inhibitor, for the treatment of major depressive disorder. Khedezla is not approved for use in pediatric patients.  The recommended dosage is 50 mg once daily with or without food. The tablets should be taken whole. For discontinuation, the dose should be reduced gradually when possible.
Dosage Form: Extended-release tablets: 50 and 100 mg
For More Information: www.accessdata.fda.gov/drugsatfda_docs/label/2013/204683s001lbl.pdf


Mekinist
Marketed by: GlaxoSmithKline
Indication: The FDA has approved Mekinist (trametinib), a kinase inhibitor, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test. Mekinist is not indicated for the treatment of patients who have received prior BRAF-inhibitor therapy. The recommended dosage is 2 mg orally once daily, at least 1 hour before or at least 2 hours after a meal.
Dosage Form: Tablets: 0.5, 1, and 2 mg
For More Information: www.mekinist.com

 
Tafinlar
Marketed by: GlaxoSmithKline
Indication: The FDA has approved Tafinlar (dabrafenib), a kinase inhibitor, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test. Tafinlar is not indicated for treatment of patients with wild-type BRAF melanoma. The recommended dosage is 150 mg orally twice daily, at least 1 hour before or at least 2 hours after a meal.
Dosage Form: Capsules: 50 or 75 mg
For More Information: www.tafinlar.com



Related Articles
Even short-term treatment with nonsteroidal anti-inflammatory drugs is associated with significant increases in bleeding and cardiovascular event risk in patients receiving antithrombotic therapy after a heart attack.
Most people hear “hospice” and think “cancer,” but many end-stage chronic obstructive pulmonary disease patients also receive hospice care when their caregivers can no longer provide the medical attention they need.
Dispensing higher opioid doses to chronic pain patients could trigger depression.
Narcotics are not recommended for managing chronic pain in children with inflammatory bowel disease, due to gastrointestinal side effects and potential dependence. Nevertheless, researchers have uncovered that long-term narcotic use is more than twice as prevalent in pediatric IBD patients compared with the general population.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$